Drug
Volulyte 6
Volulyte 6: highest development phase Post-Market, developed by Fresenius Kabi. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Fresenius Kabi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Volulyte 6% NCT03278548 | Post-Market | Hypovolaemia Due to Acute Blood Loss |
| Volulyte 6% NCT03338218 | Post-Market | Hypovolemia Due to Acute Blood Loss |
Latest
No recent events.
Follow Volulyte 6 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.